Q1 2026 was a rough quarter. The S&P 500 dropped 4.33%, Middle East tensions hammered energy prices, AI fears sparked a “SaaS-pocalypse,” and private credit markets were rattled enough that most BDCs restricted redemptions. Against that backdrop, Royalty Pharma (NASDAQ: RPRX) gained 25.6%. That kind of divergence doesn’t happen by accident.
Patient Capital Management, a Baltimore-based value shop, called RPRX its top Q1 contributor in its recently published investor letter. The core of their argument: Royalty Pharma is the world’s largest buyer of biopharmaceutical royalties, and the business model is almost uniquely positioned to be boring in the best possible way. Instead of developing drugs (with all the binary clinical risk that entails), RPRX provides capital to drug developers in exchange for a percentage of future revenues. The result is a portfolio of highly predictable, royalty-based cash flows spread across dozens of approved products. No pipeline roulette. No FDA approval anxiety.
The numbers that caught Patient Capital’s eye: the company consistently achieves unlevered internal rates of return in the low teens and levered returns in the high teens. In an environment where most “safe” fixed-income plays are yielding 4-5%, those numbers look attractive. RPRX trades at $47.90 with a $27.71 billion market cap, and hedge fund interest is rising — 39 funds held the stock at the end of Q4 2025, up from 34 the quarter before.
Patient Capital’s thesis is compounding, not momentum: they see RPRX delivering mid-teens total returns through a combination of royalty portfolio growth, dividend growth, and share buybacks. The company actively seeks deals where large pharma or early-stage biotechs need non-dilutive financing — a pipeline that gets larger, not smaller, when biotech funding gets tight.
In a market where investors are hunting for names with predictable cash flows that don’t depend on AI capex cycles, interest rate pivots, or geopolitical calm, RPRX stands out. It’s not a trade — it’s the kind of position a portfolio manager reaches for when they want to sleep at night. The fact that it outperformed by nearly 30 percentage points in a down quarter is the headline. The sustainable royalty engine underneath is the reason to pay attention.
